Ibrutinib is a well-tolerated and effective therapy used for the treatment of chronic lymphocytic leukemia (CLL). Its use has been associated with cardiovascular events such as atrial fibrillation (Afib), hypertension, and ventricular arrhythmias. Implanted loop recorders are a useful tool in guiding the management of patients with cardiac arrhythmias
Clinical trials demonstrated that ibrutinib was well-tolerated and improved clinical efficacy in adu...
The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cel...
The Bruton tyrosine kinase inhibitor ibrutinib (IB) has attained an important role in the treatment ...
The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic m...
Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological ...
Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatme...
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cel...
Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-kno...
Abstract Background Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase, indicat...
Introduction: Ibrutinib is a Bruton tyrosine kinase inhibitor indicated in the treatment of B-cell m...
Background: The natural history of chronic lymphocytic leukemia (CLL) was dramatically improved by t...
The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cel...
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use...
IntroductionIbrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the tre...
Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic l...
Clinical trials demonstrated that ibrutinib was well-tolerated and improved clinical efficacy in adu...
The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cel...
The Bruton tyrosine kinase inhibitor ibrutinib (IB) has attained an important role in the treatment ...
The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic m...
Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological ...
Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatme...
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cel...
Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-kno...
Abstract Background Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase, indicat...
Introduction: Ibrutinib is a Bruton tyrosine kinase inhibitor indicated in the treatment of B-cell m...
Background: The natural history of chronic lymphocytic leukemia (CLL) was dramatically improved by t...
The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cel...
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use...
IntroductionIbrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the tre...
Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic l...
Clinical trials demonstrated that ibrutinib was well-tolerated and improved clinical efficacy in adu...
The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cel...
The Bruton tyrosine kinase inhibitor ibrutinib (IB) has attained an important role in the treatment ...